HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.0500
-0.0050 (-9.09%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.0550
Open0.0550
Bid0.0500 x 0
Ask0.0550 x 0
Day's Range0.0450 - 0.0600
52 Week Range0.0450 - 0.7400
Volume14,802,842
Avg. Volume2,148,517
Market Cap75.801M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation
    CNW Group

    FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation

    TORONTO, Oct. 11, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company") today announced the appointment of former U.S. congressman Stephen Buyer to the Company's Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares ("Class A Shares") and its class B subordinate voting shares ("Class B Shares" and collectively with the Class A Shares, the "FSD Shares"), each on a 1 to 201 basis (the "Consolidation").

  • Business Wire

    FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") is pleased to provide an update on its previously announced private placement of its class B subordinate voting shares (“Shares”) at a price of CAD$0.10 per Share (the “Private Placement”). On September 30, 2019, the Company closed an initial tranche of the Private Placement, raising gross proceeds of CAD $4,583,085 from investors, including members of senior management and board of directors, and issuing an aggregate of 45,830,850 Shares. The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws.

  • Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's LOI with World Class Extractions Creating JV to Build and Operate Cannabis Extraction/Processing Facility in Cobourg, Ontario - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - September 26, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), through its wholly-owned subsidiary FV Pharma, has signed a letter of intent with World Class Extractions (CSE: PUMP) (FSE: WCF) to create a joint venture to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario. FSD Pharma and World Class Extractions will each hold a 50% interest in the new joint venture, ...

  • Business Wire

    FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD Pharma”, “FSD” or “the Company”) today announced the signing of a letter of intent (“LOI”) to establish a joint venture (the “Joint Venture”) with the Company’s wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), and World-Class Extractions Inc. (“World-Class”) (CSE:PUMP) (WCF.F) to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario (the “Facility”) to extract various cannabidiol and other valuable elements from cannabis and hemp plants.

  • FSD Pharma Announces Private Placement
    CNW Group

    FSD Pharma Announces Private Placement

    TORONTO, Aug. 30, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA:0K9.F - News) ("FSD" or the "Company") is pleased to announce that the Company has launched a private placement of up to US$5 million of its class B subordinate voting shares ("Shares") at a price of C$0.10 per Share without any warrant coverage (the "Private Placement"). The Company expects to close the Private Placement by September 30, 2019. To date, C$1,314,000 million of proceeds have been committed and received. The CEO has personally invested US$500,000 and the FSD Pharma leadership team, representing founders, directors and members of the senior management team have collectively invested more than C$500,000.

  • FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment
    CNW Group

    FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment

    Orders for medicinal cannabis can be placed on fvpharma.com TORONTO , Aug. 21, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company") today announced the ...

  • GlobeNewswire

    Aura Announces Pharmadrug Operational & Investor Relations Update

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF) is pleased to provide an operational update on Pharmadrug Production GmbH (the “German Business” or “Pharmadrug”) and additional resources allocated to investor relations. Following Aura’s German operational update on June 5, 2019, Pharmadrug received its second, much larger shipment of medical cannabis from Netherlands at the end of June.

  • GlobeNewswire

    Leo Acquisitions and CBx Brands Announce Letter of Intent for Proposed Qualifying Transaction

    Leo Acquisitions Corp. (LEQ-H.V) (“Leo” or the “Company”) and CBx Brands Inc. (“CBx”) are pleased to announce that they have entered into a letter of intent (the “LOI”), dated July 10, 2019, pursuant to which the Company and CBx have agreed to complete a transaction (the “Transaction”) that will result in a reverse take-over of the Company by the shareholders of CBx. It is intended that the Transaction will constitute the "Qualifying Transaction" of the Company as such term is defined in Policy 2.4 of the Corporate Finance Manual (the “Policy”) of the TSX Venture Exchange (the “TSXV”).

  • FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals
    CNW Group

    FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals

    TORONTO, July 2, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD Pharma" or the "Company") and Prismic Pharmaceuticals Inc. ("Prismic"), a US-based specialty R&D pharmaceutical company (the "Parties"), announced today that, on June 28, 2019, they finalized the acquisition by FSD Pharma of all of the issued and outstanding securities of Prismic (the "Transaction"). Pursuant to the terms of a previously-announced securities exchange Agreement, FSD Pharma has acquired all outstanding common and preferred shares of Prismic for an aggregate purchase price of approximately US$17.5 million (CAD$23.4 million based on an exchange rate of US$1 to CAD$1.3349), satisfied by the issuance of approximately 102.7 million Class B subordinate voting shares in the capital of FSD Pharma (each, an "FSD Share") at a deemed price of CAD$0.2275 (US$0.1704) per FSD Share.

  • Business Wire

    FSD Pharma Receives Full “Sale for Medical Purposes” Cannabis License from Health Canada

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”) has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The latest amendment to the license, originally granted on April 18, 2019, allows the FSD facility in Cobourg, Ontario to supply and sell cannabis products, including dried and fresh cannabis to the medicinal use marketplace.

  • FSD Pharma Receives Full "Sale for Medical Purposes" Cannabis License from Health Canada
    CNW Group

    FSD Pharma Receives Full "Sale for Medical Purposes" Cannabis License from Health Canada

    TORONTO, June 24, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company"), announced today that its wholly-owned subsidiary FV Pharma Inc. ("FV Pharma") has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The latest amendment to the license, originally granted on April 18, 2019, allows the FSD facility in Cobourg, Ontario to supply and sell cannabis products, including dried and fresh cannabis to the medicinal use marketplace. FV Pharma can now begin delivering cannabis to patients who hold prescriptions from authorized healthcare providers.

  • Newsfile

    FSD Pharma Continues to Add Expert Advisors Amid Buildout of Massive Facility -- CFN Media

    Seattle, Washington--(Newsfile Corp. - June 14, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF). The company has been focused on building out its board of directors and advisory board since becoming a full Canadian licensed producer earlier this year. After receiving its cultivation license in 2017, the company ...

  • FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors
    CNW Group

    FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors

    TORONTO, June 12, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company"), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company's Board of Directors. "It is an honor to welcome Jim Datin and Bob Ciaruffoli to the FSD Pharma Board of Directors," said Dr. Raza Bokhari, Executive Co-Chairman and CEO. "The experience and expertise they both bring as c-level entrepreneurial executives, leaders and board members of impressive organizations will add tremendous value to FSD.

  • Business Wire

    FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company’s Board of Directors. “It is an honor to welcome Jim Datin and Bob Ciaruffoli to the FSD Pharma Board of Directors,” said Dr. Raza Bokhari, Executive Co-Chairman and CEO. “The experience and expertise they both bring as c-level entrepreneurial executives, leaders and board members of impressive organizations will add tremendous value to FSD.

  • Business Wire

    FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company”), is pleased to announce the addition of two distinguished cannabis researchers to the company’s Scientific Advisory Board (“SAB”). “It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory Loflin to our Scientific Advisory Board. The board, which also includes Dr. Daniel Piomelli and Dr. Ryan Vandrey, is shaping into a very robust body of scientists and researchers under the leadership of my good friend Dr. Pollack and I commend him for his leadership.

  • FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board
    CNW Group

    FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board

    TORONTO, June 6, 2019 /CNW/ - FSD Pharma Inc. (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) ("FSD" or the "Company"), is pleased to announce the addition of two distinguished cannabis researchers to the company's Scientific Advisory Board ("SAB"). "It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory Loflin to our Scientific Advisory Board.

  • Newsfile

    FSD Pharma Brings in World-Renowned Experts to Build Bioscience Division -- CFN Media

    Seattle, Washington--(Newsfile Corp. - June 4, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF). The company may be known for having one of the largest cultivation footprints in the world with nearly 70 acres and four million square feet, but it's equally focused on advancing the science behind ...

  • Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention
    CNW Group

    Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention

    Panel to Feature Discussion About Creating a Winning Culture in the Biotech Industry TORONTO , June 3, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), ...